Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights
February 25, 2021 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
WEST CONSHOHOCKEN, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its fourth quarter and full year 2020 financial results and highlights. “We...
Casana Raises $14 Million in Series A Funding Led by General Catalyst for In-home Heart Health Monitoring Device
February 03, 2021 08:12 ET
|
Casana Care, Inc.
ROCHESTER, N.Y., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Casana, previously known as Heart Health Intelligence, Inc., a healthcare technology firm that is re-inventing in-home health monitoring, today...
Biomarkers Market Size Worth $115.45 Billion By 2027 | CAGR of 13.6%: Reports And Data
December 11, 2020 11:21 ET
|
Reports and Data
New York, Dec. 11, 2020 (GLOBE NEWSWIRE) -- The market growth is driven by technological advancements in post-genomic technologies and extensive applications of diagnostic biomarkers in precision...
Global Atrial Fibrillation Treatment Market (2020 to 2025) - Industry Trends, Share, Size, Growth, Opportunity and Forecast
December 10, 2020 04:13 ET
|
Research and Markets
Dublin, Dec. 10, 2020 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to...
Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial
November 13, 2020 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
Dr. Stephen Harrison will present Resmetirom for the Treatment of NASH: Early Data from the Phase 3 MAESTRO Clinical Trials | The Liver Meeting Digital Experience™, AASLD Product Theater on Friday,...
Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights
November 05, 2020 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in...
Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol
October 16, 2020 07:30 ET
|
Novartis International AG
If approved, inclisiran will be the first and only small interfering RNA (siRNA) in Europe for patients with hypercholesterolemia or mixed dyslipidemia1Cardiovascular disease (CVD) claims 3.9...
Madrigal Pharmaceuticals Announces Three Abstracts Accepted by The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting in November 2020, including Positive Data from Ongoing Open Label Arm of Resmetirom 52 Week Phase 3 MAESTRO-NAFLD-1 Trial
October 01, 2020 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
High accuracy in predicting advanced NASH fibrosis (F2-F3) in Phase 3 MAESTRO-NASH study using clinical characteristics and simple, readily available non-invasive imaging and biomarkersData from...
Study: Reducing Lead Exposure Has Massive Benefit for Adult Population
September 23, 2020 10:11 ET
|
Abt Associates
Rockville, Md., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Rockville, Md. – An Abt Associates-led study finds that reduction in lead exposure over the past 15 years has decreased the number of...
Madrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 Trial
September 03, 2020 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
--Completion of enrollment in MAESTRO-NAFLD-1 will enable reporting of topline 52-week data by the end of next year as planned.--Madrigal intends to present selected data from ongoing open label arm...